Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.
Volume 30, Number 11—November 2024
Synopsis
Mortality Rates after Tuberculosis Treatment, Georgia, USA, 2008–2019
Table 2
TB diagnosis and treatment characteristics stratified according to posttreatment death, HIV infection, and place of birth in study of mortality rates after TB treatment, Georgia, USA, 2008–2019*
| Characteristics | No. (%) patients |
|||
|---|---|---|---|---|
| Overall cohort | Posttreatment deaths | HIV positive | US-born persons | |
| Total no. patients |
3,218 |
233 |
328 |
1,557 |
| Case verification | ||||
| Culture confirmed | 2,391 (75) | 190 (8) | 243 (10) | 1,213 (51) |
| Clinical case | 743 (23) | 39 (5) | 83 (11) | 327 (44) |
| Other† |
48 (2) |
4 (8) |
2 (4) |
17 (35) |
| Site of TB disease | ||||
| Pulmonary | 2,551 (80) | 202 (8) | 270 (11) | 1,306 (51) |
| Extrapulmonary TB |
631 (20) |
31 (5) |
58 (9) |
251 (40) |
| Cavitary disease, n = 2,551 patients with pulmonary disease‡ | ||||
| No | 1,513 (59) | 116(8) | 214 (14) | 729 (48) |
| Yes |
1,038 (41) |
86 (8) |
56 (5) |
577 (56) |
| Sputum smear, n = 2,551 patients with pulmonary disease‡ | ||||
| Negative | 1,254 (49) | 95 (8) | 137 (11) | 650 (52) |
| Positive | 1,192 (47) | 98 (8) | 124 (10) | 600 (50) |
| Missing data |
105 (4) |
9 (9) |
9 (9) |
56 (53) |
| Drug susceptibility, n = 2,357 patients with available results‡ | ||||
| RIF/INH susceptible | 2,077 (88) | 167 (8) | 189 (9) | 1,029 (50) |
| RIF susceptible/INH resistant | 250 (11) | 20 (8) | 50 (20) | 158 (63) |
| RIF resistant |
30 (1) |
1 (3) |
3 (10) |
10 (33) |
| Completed tuberculosis treatment | ||||
| Yes | 2,973 (93) | 218 (7) | 303 (10) | 1,514 (51) |
| No | 211 (7)§ | 15 (7) | 25 (12) | 43 (21) |
*INH, isoniazid; RIF, rifampin; TB, tuberculosis. †Other comprised positive smear/tissue (n = 6) and positive nucleic acid amplification (n = 42). ‡Number of patients used in denominator to calculate percentage in overall cohort column. §Incomplete treatment included adverse treatment events (n = 11), uncooperative or refused treatments (n = 12), lost to follow-up (n = 87), moved out of jurisdiction (n = 6), or reason was missing (n = 95).
1Current affiliation: University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.